<?xml version='1.0' encoding='utf-8'?>
<document id="28349387"><sentence text="Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects."><entity charOffset="10-21" id="DDI-PubMed.28349387.s1.e0" text="Semaglutide" /><entity charOffset="49-58" id="DDI-PubMed.28349387.s1.e1" text="Metformin" /><entity charOffset="60-68" id="DDI-PubMed.28349387.s1.e2" text="Warfarin" /><entity charOffset="70-82" id="DDI-PubMed.28349387.s1.e3" text="Atorvastatin" /><entity charOffset="87-94" id="DDI-PubMed.28349387.s1.e4" text="Digoxin" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e0" e2="DDI-PubMed.28349387.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e0" e2="DDI-PubMed.28349387.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e0" e2="DDI-PubMed.28349387.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e0" e2="DDI-PubMed.28349387.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e0" e2="DDI-PubMed.28349387.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e1" e2="DDI-PubMed.28349387.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e1" e2="DDI-PubMed.28349387.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e1" e2="DDI-PubMed.28349387.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e1" e2="DDI-PubMed.28349387.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e2" e2="DDI-PubMed.28349387.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e2" e2="DDI-PubMed.28349387.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e2" e2="DDI-PubMed.28349387.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e3" e2="DDI-PubMed.28349387.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s1.e3" e2="DDI-PubMed.28349387.s1.e4" /></sentence><sentence text="Semaglutide is a glucagon-like peptide-1 analogue in development for the once-weekly treatment of type 2 diabetes mellitus"><entity charOffset="0-11" id="DDI-PubMed.28349387.s2.e0" text="Semaglutide" /></sentence><sentence text=" Its effect on the rate and extent of absorption of concomitant oral medications (metformin, warfarin, atorvastatin and digoxin) was evaluated in healthy subjects"><entity charOffset="82-91" id="DDI-PubMed.28349387.s3.e0" text="metformin" /><entity charOffset="93-101" id="DDI-PubMed.28349387.s3.e1" text="warfarin" /><entity charOffset="103-115" id="DDI-PubMed.28349387.s3.e2" text="atorvastatin" /><entity charOffset="120-127" id="DDI-PubMed.28349387.s3.e3" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e0" e2="DDI-PubMed.28349387.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e0" e2="DDI-PubMed.28349387.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e0" e2="DDI-PubMed.28349387.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e0" e2="DDI-PubMed.28349387.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e1" e2="DDI-PubMed.28349387.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e1" e2="DDI-PubMed.28349387.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e1" e2="DDI-PubMed.28349387.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e2" e2="DDI-PubMed.28349387.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s3.e2" e2="DDI-PubMed.28349387.s3.e3" /></sentence><sentence text="" /><sentence text="Subjects received metformin (500 mg twice daily for 3"><entity charOffset="18-27" id="DDI-PubMed.28349387.s5.e0" text="metformin" /></sentence><sentence text="5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0"><entity charOffset="40-52" id="DDI-PubMed.28349387.s6.e0" text="atorvastatin" /><entity charOffset="77-84" id="DDI-PubMed.28349387.s6.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.28349387.s6.e0" e2="DDI-PubMed.28349387.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28349387.s6.e0" e2="DDI-PubMed.28349387.s6.e1" /></sentence><sentence text="5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1" /><sentence text="0 mg)" /><sentence text=" Lack of drug-drug interaction was concluded if the 90% confidence intervals for the area under the plasma concentration-time curve ratio before and with semaglutide were within a pre-specified interval (0"><entity charOffset="154-165" id="DDI-PubMed.28349387.s9.e0" text="semaglutide" /></sentence><sentence text="80-1" /><sentence text="25)" /><sentence text="" /><sentence text="Overall, metformin, warfarin, atorvastatin and digoxin pharmacokinetics were not affected to a clinically relevant degree with semaglutide co-administration"><entity charOffset="9-18" id="DDI-PubMed.28349387.s13.e0" text="metformin" /><entity charOffset="20-28" id="DDI-PubMed.28349387.s13.e1" text="warfarin" /><entity charOffset="30-42" id="DDI-PubMed.28349387.s13.e2" text="atorvastatin" /><entity charOffset="47-54" id="DDI-PubMed.28349387.s13.e3" text="digoxin" /><entity charOffset="127-138" id="DDI-PubMed.28349387.s13.e4" text="semaglutide" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e0" e2="DDI-PubMed.28349387.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e0" e2="DDI-PubMed.28349387.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e0" e2="DDI-PubMed.28349387.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e0" e2="DDI-PubMed.28349387.s13.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e0" e2="DDI-PubMed.28349387.s13.e4" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e1" e2="DDI-PubMed.28349387.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e1" e2="DDI-PubMed.28349387.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e1" e2="DDI-PubMed.28349387.s13.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e1" e2="DDI-PubMed.28349387.s13.e4" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e2" e2="DDI-PubMed.28349387.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e2" e2="DDI-PubMed.28349387.s13.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e2" e2="DDI-PubMed.28349387.s13.e4" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e3" e2="DDI-PubMed.28349387.s13.e3" /><pair ddi="false" e1="DDI-PubMed.28349387.s13.e3" e2="DDI-PubMed.28349387.s13.e4" /></sentence><sentence text=" Estimated area under the plasma concentration-time curve ratios for all concomitant medications before and with semaglutide treatment were within the pre-specified interval"><entity charOffset="113-124" id="DDI-PubMed.28349387.s14.e0" text="semaglutide" /></sentence><sentence text=" In addition, semaglutide did not affect maximum plasma concentration of concomitant medications to a relevant degree"><entity charOffset="14-25" id="DDI-PubMed.28349387.s15.e0" text="semaglutide" /></sentence><sentence text=" Furthermore, no clinically relevant change in international normalised ratio response to warfarin was observed with semaglutide co-administration"><entity charOffset="117-128" id="DDI-PubMed.28349387.s16.e0" text="semaglutide" /></sentence><sentence text=" Most adverse events with semaglutide treatment were mild or moderate"><entity charOffset="26-37" id="DDI-PubMed.28349387.s17.e0" text="semaglutide" /></sentence><sentence text=" Adverse events with semaglutide and co-administered medication were comparable to those reported during treatment with semaglutide alone, and were mostly gastrointestinal related"><entity charOffset="21-32" id="DDI-PubMed.28349387.s18.e0" text="semaglutide" /></sentence><sentence text="" /><sentence text="No clinically significant pharmacokinetic or pharmacodynamic interactions were identified and no new safety issues observed with combined treatment with semaglutide"><entity charOffset="153-164" id="DDI-PubMed.28349387.s20.e0" text="semaglutide" /></sentence><sentence text=" This suggests that no dose adjustments should be required when semaglutide is administered concomitantly with these medications"><entity charOffset="64-75" id="DDI-PubMed.28349387.s21.e0" text="semaglutide" /></sentence><sentence text="" /></document>